Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 3/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.32 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21050244 | 0.81 | HTR2B (0.36) | HTR2BADORA3ADORA1 | |
| SCHEMBL21050265 | 0.81 | HTR2B (0.36) | HTR2BADORA3ADORA1 | |
| SCHEMBL21100463 | 0.80 | P2RY2 (0.43) | — | |
| SCHEMBL21100349 | 0.80 | LMNA (0.47) | HTR2BADORA3ADORA1HTR2CTMIGD3 | |
| Phosphoric Acid SCHEMBL21050225 | 0.78 | HTR2B (0.30) | HTR2B | |
| Phosphoric Acid SCHEMBL21050308 | 0.78 | HTR2B (0.30) | HTR2B | |
| SCHEMBL21050241 | 0.77 | HTR2B (0.32) | HTR2B | |
| SCHEMBL21100284 | 0.73 | ADORA3 (0.57) | ADORA3ADORA1HSP90AA1HSP90B1 | |
| SCHEMBL2173172 | 0.73 | LRRK2 (0.36) | HTR2B | |
| SCHEMBL21257360 | 0.72 | ADORA3 (0.60) | HTR2BADORA3ADORA1HTR2CTMIGD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11040975-B2 | Carbocyclic nucleoside reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20190177326-A1 | CARBOCYCLIC NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040975-B2 | Carbocyclic nucleoside reverse transcriptase inhibitors | SAMHD1, POLRMT, RNGTT | HTR2B 3381/4885ADORA3 712/4885ADORA1 616/4885 |
| US-20190177326-A1 | CARBOCYCLIC NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | SAMHD1, POLRMT, RNGTT | HTR2B 3381/4885ADORA3 712/4885ADORA1 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.